Centessa Pharmaceuticals (CNTA) Proxy filing summary

Executive summary

• A definitive agreement was reached for the acquisition of all issued and to be issued shares by a subsidiary of the acquirer, via a UK court-sanctioned scheme of arrangement, with the target becoming a wholly owned subsidiary upon closing.

• Shareholders will receive $38.00 per share in cash plus a non-transferable contingent value right (CVR) for up to $9.00 per share, contingent on regulatory milestones.

• The transaction values the equity at approximately $6.3 billion upfront, with an additional $1.5 billion possible through CVRs.

• The transaction is expected to close in the third quarter, subject to shareholder, court, and regulatory approvals.

• The acquisition expands the acquirer's neuroscience portfolio, particularly in sleep-wake disorder therapeutics.

Voting matters and shareholder proposals

• Approval of the scheme of arrangement requires at least 75% in value and number of voting shareholders at the scheme meeting and general meeting.

• Voting and support agreements have been signed by major shareholders representing about 24% of outstanding shares, committing to vote in favor of the transaction.

• Shareholders will vote on the scheme and related resolutions, with proxy materials to be filed and distributed.

Board of directors and corporate governance

• The board of directors unanimously recommends the transaction as being in the best interests of shareholders.

• Upon closing, certain directors and officers will resign as determined by the acquirer.

• The board received fairness opinions from two independent financial advisors regarding the transaction consideration.